A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary research question of this study is: Does the pharmacokinetics of oseltamivir after a single oral dose differ between the pregnant and non-pregnant women?
| Condition | Intervention | Phase |
|---|---|---|
|
Pregnancy Influenza |
Drug: Oseltamivir (Tamiflu) Procedure: Blood Draws |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy |
- Change in the area under the concentration vs. time curve (AUC 0-7 d) in the first and second trimesters of pregnancy with comparisons to the post-termination non-pregnant follow-up data on these enrollees and historical non-pregnant data. [ Time Frame: Less than 9 weeks for subjects planning termination; up to 5 months for subjects enrolled during their 3rd trimester. ] [ Designated as safety issue: No ]
- Non-compartmental model analysis for Cmax, Tmax, Cl/F, Clr,V/F, MRT and t ½. [ Time Frame: Less than 9 weeks for subjects planning termination; up to 5 months for subjects enrolled during their 3rd trimester. ] [ Designated as safety issue: No ]
- Plasma concentrations of oseltamivir after single-dosing. [ Time Frame: Less than 9 weeks for subjects planning termination; up to 5 months for subjects enrolled during their 3rd trimester. ] [ Designated as safety issue: No ]
- Evaluation of carboxy-esterase levels and activity in all trimesters of pregnancy with comparison to the post-partum internal controls. [ Time Frame: Less than 9 weeks for subjects planning termination; up to 5 months for subjects enrolled during their 3rd trimester. ] [ Designated as safety issue: No ]
- Tolerance (side effect profile) of single-dose oseltamivir in pregnancy. [ Time Frame: Less than 9 weeks for subjects planning termination; up to 5 months for subjects enrolled during their 3rd trimester. ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 39 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Oseltamivir (Tamiflu) |
Drug: Oseltamivir (Tamiflu)
The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure. A) Subject will take 75 mg of oseltamivir pill by mouth B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected. |
| Esterase |
Procedure: Blood Draws
Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
|
Detailed Description:
With the pending threat of pandemic avian influenza, the disproportionate morbidity and mortality documented in previous 20th century pandemics among pregnant women, and the lack of any data for use of these vital antiviral drugs in pregnancy, study of the pharmacology of oseltamivir in pregnancy is imperative. If and when the next pandemic occurs, a better understanding of this drug's safety and pharmacologic profiles for use in pregnancy is critical given the fact that it will be used in this vulnerable patient population.
This is a pilot study of the use of oseltamivir in pregnancy. This data will be combined with data from the parallel Pediatric Pharmacology Research Unit (PPRU) studies to put together a portfolio for use in understudied populations. This will allow for a re-thinking of the current status and potentially allow for small trials to be performed with patients who are suffering from influenza in pregnancy, to assess efficacy. The relevance with the pandemic strain and its corresponding Minimum Inhibitory Concentration (MIC) may have direct implications for dosing in pregnancy if lower levels of drug are documented. In addition, depending on the findings from the esterase component of the investigation, future investigation into mechanistic bases for changes in enzyme activity are possible.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- For Oseltamivir (Tamiflu) arm:
- Singleton gestation prior to 24 0/7 weeks gestation
- Planning to undergo a termination procedure for the incident pregnancy
- Willingness to take the single-dose medication and to follow study procedures
- Able to undergo informed consent.
- For Esterase arm:
- Singleton gestation greater than 32 completed weeks and less than 40 completed weeks of gestation
- Absence of severe pregnancy complication that could affect body volume and or metabolism (i.e., preeclampsia, renal dysfunction, hepatic dysfunction [defined as serum creatinine clearance of < 30 ml/min or a known ALT/AST> 2x facility normal value], etc.)
- Willingness to follow study procedures
- Able to undergo informed consent
- The use of medications that may affect renal metabolism is not a contraindication to participation since these subjects are only undergoing PK sampling.
Exclusion Criteria:
- For Oseltamivir (Tamiflu) arm:
- Known current in utero fetal death
- Significant medical history and/or medication use as determined by the investigator that has the potential to affect results of the study or put the patient at risk from the single-dosing
- Known hypersensitivity to the components of the study drug
- Known hepatic or renal dysfunction (defined as serum creatinine clearance of < 30 ml/min or a known ALT/AST> 2x facility normal value)
- Chronic use of street drugs (obtained via subject interview and/or medical history)
- Participation in any other concurrent interventional study.
- We will ask if they have a history of depression in the past requiring treatment or if they are currently actively depressed. If either of these questions yields a positive response, we will not consider the patient eligible and will not enroll the subject.
- For Esterase arm:
- Known current in utero fetal death
- Significant medical history as determined by the investigator to potentially affect results of the study
- Chronic use of street drugs (obtained via subject interview and/or medical history
- Participation in any other concurrent interventional study.
Contacts and Locations| United States, Pennsylvania | |
| Magee-Womens Hospital of University of Pittsburgh Medical Center | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Principal Investigator: | Richard H. Beigi, MD | University of Pittsburgh |
More Information
Publications:
| Responsible Party: | Richard H. Beigi, MD, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00873886 History of Changes |
| Other Study ID Numbers: | IRB #PRO07080362, NIH Grant #5U10HD047905-02 |
| Study First Received: | April 1, 2009 |
| Last Updated: | November 2, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases Oseltamivir |
Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013